 | Up a level |
Hruska-Plochan, Marian; Wiersma, Vera I; Betz, Katharina M; Mallona, Izaskun; Ronchi, Silvia; Maniecka, Zuzanna; Hock, Eva-Maria; Tantardini, Elena; Laferriere, Florent; Sahadevan, Sonu; Hoop, Vanessa; Delvendahl, Igor; Pérez-Berlanga, Manuela; Gatta, Beatrice; Panatta, Martina; van der Bourg, Alexander; Bohaciakova, Dasa; Sharma, Puneet; De Vos, Laura; Frontzek, Karl; ... (2024). A model of human neural networks reveals NPTX2 pathology in ALS and FTLD. Nature, 626(8001), pp. 1073-1083. Springer Nature 10.1038/s41586-024-07042-7
Zander, Thilo; Pabst, Thomas; Schär, Sämi; Aebi, Stefan; Mey, Ulrich; Novak, Urban; Lerch, Erika; Rhyner Agocs, Gaëlle; Goede, Jeroen; Maniecka, Zuzanna; Hayoz, Stefanie; Rüfer, Axel; Renner, Christoph; Driessen, Christoph (2023). Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia, 37(3), pp. 699-701. Springer Nature 10.1038/s41375-023-01809-z
Zander, Thilo; Pabst, Thomas; Schär, Sämi; Aebi, Stefan; Pabst, Tobias; Mey, Ulrich; Novak, Urban; Lerch, Erika; Rhyner, Gaëlle; Goede, Jeroen; Maniecka, Zuzanna; Hayoz, Stefanie; Rufer, Axel; Renner, Christoph; Driessen, Christoph (2021). P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study). Clinical lymphoma, myeloma and leukemia, 21(Suppl. 2), S165-S165. Elsevier 10.1016/S2152-2650(21)02354-5
